B

Biovaxys Technology Corp
CNSX:BIOV

Watchlist Manager
Biovaxys Technology Corp
CNSX:BIOV
Watchlist
Price: 0.19 CAD -5% Market Closed
Market Cap: 8.1m CAD

Biovaxys Technology Corp
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Biovaxys Technology Corp
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
B
Biovaxys Technology Corp
CNSX:BIOV
Research & Development
-CA$1.5k
CAGR 3-Years
87%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abcellera Biologics Inc
NASDAQ:ABCL
Research & Development
-$167.3m
CAGR 3-Years
-39%
CAGR 5-Years
-75%
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Research & Development
-$66.6m
CAGR 3-Years
17%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Research & Development
-$29.7m
CAGR 3-Years
14%
CAGR 5-Years
10%
CAGR 10-Years
-7%
Willow Biosciences Inc
TSX:WLLW
Research & Development
-CA$5.1m
CAGR 3-Years
22%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
NervGen Pharma Corp
XTSX:NGEN
Research & Development
-CA$14.8m
CAGR 3-Years
-5%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
No Stocks Found

Biovaxys Technology Corp
Glance View

Market Cap
8.1m CAD
Industry
N/A

BioVaxys Technology Corp. is a clinical stage biotechnology company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-11-21. The firm is focused on developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is using its haptenized antigen technology platforms to develop vaccines to treat viral infections, such as SARS-CoV-2, human papillomavirus (HPV) and cancers, such as late-stage ovarian cancer, cervical cancer and melanoma. Its product portfolio includes BVX-0320, BVX-0121, BVX-0204, BVX-0918A, BVX-0918C, CoviDTH and Papilocare. BVX-0320 is an investigational new drug (IND)-stage vaccine candidate for SARS-CoV-2. The vaccine is the recombinant S1 subunit of the spike protein of SARS-CoV-2 that has been modified with a chemical called hapten, specifically, dinitrophenyl (DNP). Its CoviDTH is a disposable, diagnostic tool to identify a T-cell immune response to the presence of SARS-CoV-2. BVX-0918A is a haptenized tumor cell vaccine for ovarian cancer.

BIOV Intrinsic Value
0.003 CAD
Overvaluation 98%
Intrinsic Value
Price
B

See Also

What is Biovaxys Technology Corp's Research & Development?
Research & Development
-1.5k CAD

Based on the financial report for Oct 31, 2024, Biovaxys Technology Corp's Research & Development amounts to -1.5k CAD.

What is Biovaxys Technology Corp's Research & Development growth rate?
Research & Development CAGR 3Y
87%

Over the last year, the Research & Development growth was 99%. The average annual Research & Development growth rates for Biovaxys Technology Corp have been 87% over the past three years .

Back to Top